<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BENZACLIN - clindamycin phosphate and benzoyl peroxide gel </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Topical Gel: clindamycin  (1%) as clindamycin phosphate, benzoyl peroxide (5%)<br>For Dermatological Use Only - Not for Ophthalmic Use<br>*SAMPLE. NO RECONSTITUTION NECESSARY*</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">BenzaClin<span class="Sup">®</span> Topical Gel</span> contains clindamycin phosphate, (7(S)-chloro-7-deoxylincomycin-2-phosphate). Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.</p>
<p>Chemically, clindamycin phosphate is (C<span class="Sub">18</span>H<span class="Sub">34</span>ClN<span class="Sub">2</span>O<span class="Sub">8</span>PS).  The structural formula for clindamycin is represented below:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1adf643-ee59-4251-bbf8-49f54265f833&amp;name=benzaclin-sample-01.jpg"></p>
<p>Clindamycin phosphate has molecular weight of 504.97 and its chemical name is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2-(dihydrogen phosphate). </p>
<p><span class="Bold">BenzaClin Topical Gel</span> also contains benzoyl peroxide, for topical use.<br>Chemically, benzoyl peroxide is (C<span class="Sub">14</span>H<span class="Sub">10</span>O<span class="Sub">4</span>). It has the following structural formula: </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1adf643-ee59-4251-bbf8-49f54265f833&amp;name=benzaclin-sample-02.jpg"></p>
<p>Benzoyl peroxide has a molecular weight of 242.23.</p>
<p>Each gram of <span class="Bold">BenzaClin Topical Gel</span> contains, as dispensed, 10 mg (1%) clindamycin as phosphate and 50 mg (5%) benzoyl peroxide in a base of carbomer, sodium hydroxide, dioctyl sodium sulfosuccinate, and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">An <span class="Italics">in vitro</span> percutaneous penetration study comparing <span class="Bold">BenzaClin Topical Gel</span> and topical 1% clindamycin gel alone, demonstrated there was no statistical difference in penetration between the two drugs.  Mean systemic bioavailability of topical clindamycin in <span class="Bold">BenzaClin Topical Gel</span> is suggested to be less than 1%.</p>
<p>Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.  Less than 2% of the dose enters systemic circulation as benzoic acid. It is suggested that the lipophilic nature of benzoyl peroxide acts to concentrate the compound into the lipid-rich sebaceous follicle.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The clindamycin and benzoyl peroxide components individually have been shown to have <span class="Italics">in vitro</span> activity against <span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> an organism which has been associated with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>; however, the clinical significance of this activity against <span class="Italics">P. <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> was not examined in clinical trials with this product.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In two adequate and well controlled clinical studies of 758 patients, 214 used BenzaClin, 210 used benzoyl peroxide, 168 used clindamycin, and 166 used vehicle. BenzaClin applied twice daily for 10 weeks was significantly more effective than vehicle in the treatment of moderate to moderately severe facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.   Patients were evaluated and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> lesions counted at each clinical visit; weeks 2, 4, 6, 8 and 10.  The primary efficacy measures were the lesion counts and the investigator's global assessment evaluated at week 10. Patients were instructed to wash the face with a mild soap, using only the hands.  Fifteen minutes after the face was thoroughly dry, application was made to the entire face.  Non-medicated make-up could be applied at one hour after the BenzaClin application.  If a moisturizer was required, the patients were provided a moisturizer to be used as needed.  Patients were instructed to avoid sun exposure.  Percent reductions in lesion counts after treatment for 10 weeks in these two studies are shown below:</p>
<a name="i09e84be6-bdc9-4f55-8b64-9b01668b894d"></a><table width="50%">
<caption><span>Study 1</span></caption>
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="center">BenzaClin</th>
<th class="Lrule" align="center">Benzoyl peroxide</th>
<th class="Lrule" align="center">Clindamycin</th>
<th class="Lrule Rrule" align="center">Vehicle</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">n=120</th>
<th class="Lrule" align="center">n=120</th>
<th class="Lrule" align="center">n=120</th>
<th class="Lrule Rrule" align="center">n=120</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4">Mean percent reduction in inflammatory lesion counts</td></tr>
<tr class="Botrule">
<td class="Lrule" align="center">46%</td>
<td class="Lrule" align="center">32%</td>
<td class="Lrule" align="center">16%</td>
<td class="Lrule Rrule" align="center">+ 3%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4">Mean percent reduction in non-inflammatory lesion counts</td></tr>
<tr class="Botrule">
<td class="Lrule" align="center">22%</td>
<td class="Lrule" align="center">22%</td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule Rrule" align="center">+1%</td>
</tr>
<tr class="Botrule"><td class="Botrule Lrule Rrule" align="center" colspan="4">Mean percent reduction in total lesion counts</td></tr>
<tr class="Last">
<td class="Lrule" align="center">36%</td>
<td class="Lrule" align="center">28%</td>
<td class="Lrule" align="center">15%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
</tbody>
</table>
<a name="i5294524a-385c-43d8-8a61-6f3183ef72d3"></a><table width="50%">
<caption><span>Study 2</span></caption>
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="center">BenzaClin</th>
<th class="Lrule" align="center">Benzoyl peroxide</th>
<th class="Lrule" align="center">Clindamycin</th>
<th class="Lrule Rrule" align="center">Vehicle</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">n=95</th>
<th class="Lrule" align="center">n=95</th>
<th class="Lrule" align="center">n=49</th>
<th class="Lrule Rrule" align="center">n=48</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4">Mean percent reduction in inflammatory lesion counts</td></tr>
<tr class="Botrule">
<td class="Lrule" align="center">63%</td>
<td class="Lrule" align="center">53%</td>
<td class="Lrule" align="center">45%</td>
<td class="Lrule Rrule" align="center">42%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4">Mean percent reduction in non-inflammatory lesion counts</td></tr>
<tr class="Botrule">
<td class="Lrule" align="center">54%</td>
<td class="Lrule" align="center">50%</td>
<td class="Lrule" align="center">39%</td>
<td class="Lrule Rrule" align="center">36%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4">Mean percent reduction in total lesion counts</td></tr>
<tr class="Last">
<td class="Lrule" align="center">58%</td>
<td class="Lrule" align="center">52%</td>
<td class="Lrule" align="center">42%</td>
<td class="Lrule Rrule" align="center">39%</td>
</tr>
</tbody>
</table>
<p>The BenzaClin group showed greater overall improvement than the benzoyl peroxide, clindamycin and vehicle groups as rated by the investigator.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">BenzaClin Topical Gel</span> is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">BenzaClin Topical Gel</span> is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components or to lincomycin.  It is also contraindicated in those having a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">ORALLY AND PARENTERALLY ADMINISTERED CLINDAMYCIN HAS BEEN ASSOCIATED WITH SEVERE <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span> WHICH MAY RESULT IN PATIENT <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.  USE OF THE TOPICAL FORMULATION OF CLINDAMYCIN RESULTS IN ABSORPTION OF THE ANTIBIOTIC FROM THE SKIN SURFACE.  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">BLOODY DIARRHEA</span>, AND <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span> (INCLUDING <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">PSEUDOMEMBRANOUS COLITIS</span>) HAVE BEEN REPORTED WITH THE USE OF TOPICAL AND SYSTEMIC CLINDAMYCIN.  STUDIES INDICATE A TOXIN(S) PRODUCED BY CLOSTRIDIA IS ONE PRIMARY CAUSE OF ANTIBIOTIC-ASSOCIATED <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span>.  THE <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span> IS USUALLY CHARACTERIZED BY SEVERE PERSISTENT <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">ABDOMINAL CRAMPS</span> AND MAY BE ASSOCIATED WITH THE PASSAGE OF BLOOD AND MUCUS. ENDOSCOPIC EXAMINATION MAY REVEAL <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">PSEUDOMEMBRANOUS COLITIS</span>.  STOOL CULTURE FOR <span class="Italics">Clostridium Difficile</span> AND STOOL ASSAY FOR <span class="Italics">C. difficile</span> TOXIN MAY BE HELPFUL DIAGNOSTICALLY.  WHEN SIGNIFICANT <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> OCCURS, THE DRUG SHOULD BE DISCONTINUED. LARGE BOWEL ENDOSCOPY SHOULD BE CONSIDERED TO ESTABLISH A DEFINITIVE DIAGNOSIS IN CASES OF SEVERE <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>.  ANTIPERISTALTIC AGENTS SUCH AS OPIATES AND DIPHENOXYLATE WITH ATROPINE MAY PROLONG AND/OR WORSEN THE CONDITION. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span>, AND <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">PSEUDOMEMBRANOUS COLITIS</span> HAVE BEEN OBSERVED TO BEGIN UP TO SEVERAL WEEKS FOLLOWING CESSATION OF ORAL AND PARENTERAL THERAPY WITH CLINDAMYCIN.</span></p>
<p>Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone.  In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">For dermatological use only; not for ophthalmic use.  Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating, or abrasive agents.</p>
<p>The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms including fungi.  If this occurs, discontinue use of this medication and take appropriate measures.</p>
<p>Avoid contact with eyes and mucous membranes.</p>
<p>Clindamycin and erythromycin containing products should not be used in combination.  <span class="Italics">In vitro</span> studies have shown antagonism between these two antimicrobials.  The clinical significance of this <span class="Italics">in vitro</span> antagonism is not known.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients using <span class="Bold">BenzaClin Topical Gel</span> should receive the following information and instructions:</p>
<ol>
<li>
<span class="Bold">BenzaClin Topical Gel</span> is to be used as directed by the physician.  It is for external use only.  Avoid contact with eyes, and inside the nose, mouth, and all mucous membranes, as this product may be irritating.</li>
<li>This medication should not be used for any disorder other than that for which it was prescribed.</li>
<li>Patients should not use any other topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> preparation unless otherwise directed by physician.</li>
<li>Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using BenzaClin Topical Gel. To minimize exposure to sunlight, a wide-brimmed hat or other protective clothing should be worn, and a sunscreen with SPF 15 rating or higher should be used.</li>
<li>Patients who develop allergic symptoms such as severe <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> should discontinue <span class="Bold">BenzaClin Topical Gel</span> and contact their physician immediately. In addition, patients should report any signs of local adverse reactions to their physician.</li>
<li>
<span class="Bold">BenzaClin Topical Gel</span> may bleach hair or colored fabric.</li>
<li>
<span class="Bold">BenzaClin Topical Gel</span> can be stored at room temperature 25°C (77°F).  Do not freeze.  Discard any unused product after expiration date on sample. </li>
<li>Before applying <span class="Bold">BenzaClin Topical Gel</span> to affected areas wash the skin gently, then rinse with warm water and pat dry.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies.  The clinical significance of this is unknown.</p>
<p>Benzoyl peroxide in acetone at doses of 5 and 10 mg administered twice per week induced <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in transgenic Tg.AC mice in a study using 20 weeks of topical treatment.</p>
<p>In a 52 week dermal photocarcinogenicity study in hairless mice, the median time to onset of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumor</span> formation was decreased and the number of tumors per mouse increased following chronic concurrent topical administration of BenzaClin Topical Gel with exposure to ultraviolet radiation (40 weeks of treatment followed by 12 weeks of observation). </p>
<p>In a 2-year dermal carcinogenicity study in rats, treatment with BenzaClin Topical Gel at doses of 100, 500 and 2000 mg/kg/day caused a dose-dependent increase in the incidence of <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span> at the treated skin site of male rats.  The incidence of <span class="product-label-link" type="condition" conceptid="4112746" conceptname="Keratoacanthoma">keratoacanthoma</span> at the treated site of males treated with 2000 mg/kg/day (8 times the highest recommended adult human dose of 2.5 g BenzaClin Topical Gel, based on mg/m<span class="Sup">2</span>) was statistically significantly higher than that in the sham- and vehicle-controls.</p>
<p>Genotoxicity studies were not conducted with BenzaClin Topical Gel.  Clindamycin phosphate was not genotoxic in <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> or in a rat micronucleus test.  Clindamycin phosphate sulfoxide, an oxidative degradation product of clindamycin phosphate and benzoyl peroxide, was not clastogenic in a mouse micronucleus test.  Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in <span class="Italics">S. typhimurium</span> tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells. Studies have not been performed with <span class="Bold">BenzaClin Topical Gel</span> or benzoyl peroxide to evaluate the effect on fertility. Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times the amount of clindamycin in the highest recommended adult human dose of 2.5 g BenzaClin Topical Gel, based on mg/m<span class="Sup">2</span>) revealed no effects on fertility or mating ability.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproductive/developmental toxicity studies have not been conducted with BenzaClin Topical Gel or benzoyl peroxide.  Developmental toxicity studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (240 and 120 times amount of clindamycin in the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (100 and 50 times the amount of clindamycin in the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>There are no well-controlled trials in pregnant women treated with <span class="Bold">BenzaClin Topical Gel</span>.  It also is not known whether <span class="Bold">BenzaClin Topical Gel</span> can cause fetal harm when administered to a pregnant woman.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.5"></a><p></p>
<h2>Nursing Women</h2>
<p class="First">It is not known whether <span class="Bold">BenzaClin Topical Gel</span> is excreted in human milk after topical application.  However, orally and parenterally administered clindamycin has been reported to appear in breast milk.  Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of this product in pediatric patients below the age of 12 have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">During clinical trials, the most frequently reported adverse event in the BenzaClin treatment group was <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> (12%).  The Table below lists local adverse events reported by at least 1% of patients in the BenzaClin and vehicle groups.</p>
<a name="i5da797a2-ee64-424c-87b5-88ec182f0369"></a><table width="50%">
<caption><span>Local Adverse Events - all causalities in &gt;/= 1% of patients </span></caption>
<col align="center" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead>
<tr class="First">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center">BenzaClin</th>
<th class="Lrule Rrule" align="center">Vehicle</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center">n = 420</th>
<th class="Lrule Rrule" align="center">n = 168</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reaction</span></td>
<td class="Lrule" align="center">13 (3%)</td>
<td class="Lrule Rrule" align="center">1 (&lt;1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Lrule" align="center">50 (12%)</td>
<td class="Lrule Rrule" align="center">10 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule" align="center">8 (2%)</td>
<td class="Lrule Rrule" align="center">1 (&lt;1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Peeling</span></td>
<td class="Lrule" align="center">9 (2%)</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Lrule" align="center">6 (1%)</td>
<td class="Lrule Rrule" align="center">1 (&lt;1%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">Sunburn</td>
<td class="Lrule" align="center">5 (1%)</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
</tbody>
</table>
<p>The actual incidence of <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> might have been greater were it not for the use of a moisturizer in these studies.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, as well as <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> leading to hospitalization, have been reported during post-marketing use of clindamycin/benzoyl peroxide products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">BenzaClin Topical Gel</span> should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is gently washed, rinsed with warm water and patted dry.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">BenzaClin Topical Gel</span> is supplied in 6 gram plastic jars  (NDC 54868-6062-0).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First">Store at room temperature 25°C (77°F).<br><span class="Bold">Do not freeze.  Refrigeration is not required.  Keep tightly closed. Keep out of the reach of children.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">US Patents 5,446,028; 5,767,098<br>Prescribing Information as of June 2009.</p>
<p><span class="Bold">Dermik Laboratories</span><br>a business of sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807</p>
<p>©2009 sanofi-aventis U.S. LLC</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50g Pump</h1>
<p class="First">NDC 54868-6062-0<br></p>
<p><span>BenzaClin</span><span class="Sup">®</span><br><span>topical gel</span></p>
<p><span>clindamycin-benzoyl peroxide gel</span></p>
<p>FOR TOPICAL USE ONLY</p>
<p>Reconstitute with Clinda–Pak<span class="Sup">®</span></p>
<p><span class="Bold">One</span> 50g <span class="Bold">Pump</span> (after reconstitution)</p>
<br><div class="Figure"><img alt="Principal Display Panel - 50g Pump" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1adf643-ee59-4251-bbf8-49f54265f833&amp;name=6062.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BENZACLIN 		
					</strong><br><span class="contentTableReg">clindamycin phosphate and benzoyl peroxide gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6062(NDC:0066-0494)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>clindamycin phosphate</strong> (clindamycin) </td>
<td class="formItem">clindamycin</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>benzoyl peroxide</strong> (benzoyl peroxide) </td>
<td class="formItem">benzoyl peroxide</td>
<td class="formItem">50 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6062-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6 g in 1 JAR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050756</td>
<td class="formItem">08/27/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>61d8c50d-47a7-409d-a3bb-b74d2a745487</div>
<div>Set id: c1adf643-ee59-4251-bbf8-49f54265f833</div>
<div>Version: 2</div>
<div>Effective Time: 20111227</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
